43 related articles for article (PubMed ID: 12939604)
1. A model for the study of hepatitis C virus entry.
Castet V; Moradpour D
Hepatology; 2003 Sep; 38(3):771-4. PubMed ID: 12939604
[TBL] [Abstract][Full Text] [Related]
2. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.
Bartosch B; Dubuisson J; Cosset FL
J Exp Med; 2003 Mar; 197(5):633-42. PubMed ID: 12615904
[TBL] [Abstract][Full Text] [Related]
3. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.
Lavillette D; Tarr AW; Voisset C; Donot P; Bartosch B; Bain C; Patel AH; Dubuisson J; Ball JK; Cosset FL
Hepatology; 2005 Feb; 41(2):265-74. PubMed ID: 15660396
[TBL] [Abstract][Full Text] [Related]
4. Detection of neutralizing antibodies with HCV pseudoparticles (HCVpp).
Dreux M; Cosset FL
Methods Mol Biol; 2009; 510():427-38. PubMed ID: 19009280
[TBL] [Abstract][Full Text] [Related]
5. Studying HCV cell entry with HCV pseudoparticles (HCVpp).
Bartosch B; Cosset FL
Methods Mol Biol; 2009; 510():279-93. PubMed ID: 19009269
[TBL] [Abstract][Full Text] [Related]
6. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.
Meunier JC; Engle RE; Faulk K; Zhao M; Bartosch B; Alter H; Emerson SU; Cosset FL; Purcell RH; Bukh J
Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4560-5. PubMed ID: 15767578
[TBL] [Abstract][Full Text] [Related]
7. The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles.
Morikawa K; Zhao Z; Date T; Miyamoto M; Murayama A; Akazawa D; Tanabe J; Sone S; Wakita T
J Med Virol; 2007 Jun; 79(6):714-23. PubMed ID: 17457918
[TBL] [Abstract][Full Text] [Related]
8. Generation of infectious HCV pseudo typed particles and its utilization for studying the role of CD81 & SRBI receptors in HCV infection.
Rafique S; Idrees M; Ali A; Sahibzada KI; Iqbal M
Mol Biol Rep; 2014 Jun; 41(6):3813-9. PubMed ID: 24549717
[TBL] [Abstract][Full Text] [Related]
9. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins.
Goffard A; Callens N; Bartosch B; Wychowski C; Cosset FL; Montpellier C; Dubuisson J
J Virol; 2005 Jul; 79(13):8400-9. PubMed ID: 15956584
[TBL] [Abstract][Full Text] [Related]
10. Characterization of classical swine fever virus entry by using pseudotyped viruses: E1 and E2 are sufficient to mediate viral entry.
Wang Z; Nie Y; Wang P; Ding M; Deng H
Virology; 2004 Dec; 330(1):332-41. PubMed ID: 15527858
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus infection in dialysis and chronic liver patients: Viraemia dependent anti-E2-antibody response.
Hanuka N; Sikuler E; Tovbin D; Neville L; Nussbaum O; Mostoslavsky M; Orgel M; Yaari A; Manor S; Dagan S; Hilzenrat N; Shemer-Avni Y
J Med Virol; 2004 Aug; 73(4):529-35. PubMed ID: 15221896
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system.
Zhu H; Dong H; Eksioglu E; Hemming A; Cao M; Crawford JM; Nelson DR; Liu C
Gastroenterology; 2007 Nov; 133(5):1649-59. PubMed ID: 17983809
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus E2 links soluble human CD81 and SR-B1 protein.
Heo TH; Lee SM; Bartosch B; Cosset FL; Kang CY
Virus Res; 2006 Oct; 121(1):58-64. PubMed ID: 16725222
[TBL] [Abstract][Full Text] [Related]
14. Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system.
Lavie M; Voisset C; Vu-Dac N; Zurawski V; Duverlie G; Wychowski C; Dubuisson J
Hepatology; 2006 Dec; 44(6):1626-34. PubMed ID: 17133472
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus entry: an intriguing challenge for drug discovery.
Meanwell NA
Curr Opin Investig Drugs; 2006 Aug; 7(8):727-32. PubMed ID: 16955684
[TBL] [Abstract][Full Text] [Related]
16. Morphological identification of hepatitis C virus E1 and E2 envelope glycoproteins on the virion surface using immunogold electron microscopy.
Kaito M; Watanabe S; Tanaka H; Fujita N; Konishi M; Iwasa M; Kobayashi Y; Gabazza EC; Adachi Y; Tsukiyama-Kohara K; Kohara M
Int J Mol Med; 2006 Oct; 18(4):673-8. PubMed ID: 16964422
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection.
Andréo U; Maillard P; Kalinina O; Walic M; Meurs E; Martinot M; Marcellin P; Budkowska A
Cell Microbiol; 2007 Oct; 9(10):2445-56. PubMed ID: 17517063
[TBL] [Abstract][Full Text] [Related]
18. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles.
Tao W; Xu C; Ding Q; Li R; Xiang Y; Chung J; Zhong J
Virology; 2009 Dec; 395(1):67-76. PubMed ID: 19793603
[TBL] [Abstract][Full Text] [Related]
19. Green fluorescent protein - Tagged HCV non-enveloped capsid like particles: development of a new tool for tracking HCV core uptake.
Katsarou K; Serti E; Tsitoura P; Lavdas AA; Varaklioti A; Pickl-Herk AM; Blaas D; Oz-Arslan D; Zhu R; Hinterdorfer P; Mavromara P; Georgopoulou U
Biochimie; 2009 Jul; 91(7):903-15. PubMed ID: 19401214
[TBL] [Abstract][Full Text] [Related]
20. In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs.
Wunschmann S; Muller HM; Stipp CS; Hemler ME; Stapleton JT
J Infect Dis; 2006 Oct; 194(8):1058-67. PubMed ID: 16991080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
